솔젤 테크놀로지스(SLGL)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $63.62 (-1.43%), 시가총액 $0.24B, 52주 최저~최고 $6.90 ~ $97.97.
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license
솔젤 테크놀로지스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
솔젤 테크놀로지스의 현재 주가는 $63.62 (-1.43%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
솔젤 테크놀로지스의 시가총액은 약 $0.24B입니다.
Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada,